Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GE Healthcare Augments IT Offerings With $1.2 Bil. Purchase Of IDX

This article was originally published in The Gray Sheet

Executive Summary

GE Healthcare is responding to increased IT competition from imaging competitors Kodak and Philips with a $1.2 bil. acquisition of health information technology firm IDX Systems

You may also be interested in...



Radiological Society Of North America Conference In Brief

Imagecast: IDX Systems launches the IDX Imagecast picture archiving and communications solutions (PACS) for orthopedics Nov. 28 at the RSNA conference in Chicago. Imagecast allows surgeons to plan orthopedic surgery with precise digital measurements and overlaying templates. It provides greater accuracy than traditional methods of mapping surgery on film images, which can be distorted by the angle of projection and variation in the magnification of different x-rays, IDX explains. GE Healthcare agreed to buy IDX in September for $1.2 bil. The deal is set to close in early 2006 (1"The Gray Sheet" Oct. 3, 2005, p. 19)...

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel